-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 9, Moderna announced that its 2022 vaccine sales reached $18.
4 billion, after CEO Stéphane
Bancel predicts $21 billion
.
In 2021, Moderna's new crown mRNA vaccine mRNA1273 had sales of $17.
675 billion
.
At this year's J.
P.
Morgan Healthcare Conference in San Francisco, Bancel identified at least $5 billion in Covid-19 vaccine sales
in 2023 through confirmed pre-purchase agreements and 2022 extension contracts.
Arpa, Moderna's Chief Commercial Officer
Garay predicts that the coronavirus vaccine market will be as big or bigger
as the flu market.
Bancel said the company is considering setting the price of the vaccine at $110 to $130 per dose in the United States
.
Moderna did not immediately comment
on pricing its vaccine.
According to multiple reports, Pfizer proposed the same vaccine price range
last fall.
Moderna CEO Stéphane Bancel
To drive growth, the company increased its R&D budget by an additional $1.
2 billion this year, for a total budget of about $4.
5 billion
.
On Monday afternoon, the company's shares rose about 2 percent to about
$184.
52 a share.
Moderna executives also revealed that Moderna purchased a new priority review voucher that can reduce FDA review of new drugs from 10 months to 6 months
.
The company also has another voucher that it received
last year with approval of its coronavirus vaccine, Spikevax.
While Moderna declined to provide more information about the new voucher, it said it intended to use both PRVs to expedite the review of the company's two upcoming BLA applications
.
The business development team remained very active last quarter, with the company acquiring OriCiro last week for $85 million
This is evidenced by Genomics and its work on cell-free synthesis and amplification of plasmid DNA
.
In broader respiratory studies, the Phase III RSV study has reached the number of cases needed for the first efficacy analysis, and flu data may be released
this quarter.
The company also hopes to launch phase III trials
of an mRNA-based cancer vaccine in combination with Merck's Keytruda for melanoma this year.
English link: _mstmutation="1" _msthash="220727" _msttexthash="5471960">
